212 related articles for article (PubMed ID: 35272484)
21. The WNK1 and WNK4 protein kinases that are mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases.
Vitari AC; Deak M; Morrice NA; Alessi DR
Biochem J; 2005 Oct; 391(Pt 1):17-24. PubMed ID: 16083423
[TBL] [Abstract][Full Text] [Related]
22. Disruption of the with no lysine kinase-STE20-proline alanine-rich kinase pathway reduces the hypertension induced by angiotensin II.
Cervantes-Perez LG; Castaneda-Bueno M; Jimenez JV; Vazquez N; Rojas-Vega L; Alessi DR; Bobadilla NA; Gamba G
J Hypertens; 2018 Feb; 36(2):361-367. PubMed ID: 28877076
[TBL] [Abstract][Full Text] [Related]
23. Cotransporters, WNKs and hypertension: an update.
Flatman PW
Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):186-92. PubMed ID: 18277153
[TBL] [Abstract][Full Text] [Related]
24. WNK-SPAK-NCC cascade revisited: WNK1 stimulates the activity of the Na-Cl cotransporter via SPAK, an effect antagonized by WNK4.
Chávez-Canales M; Zhang C; Soukaseum C; Moreno E; Pacheco-Alvarez D; Vidal-Petiot E; Castañeda-Bueno M; Vázquez N; Rojas-Vega L; Meermeier NP; Rogers S; Jeunemaitre X; Yang CL; Ellison DH; Gamba G; Hadchouel J
Hypertension; 2014 Nov; 64(5):1047-53. PubMed ID: 25113964
[TBL] [Abstract][Full Text] [Related]
25. WNK4-SPAK modulates lipopolysaccharide-induced macrophage activation.
Hung CM; Peng CK; Yang SS; Shui HA; Huang KL
Biochem Pharmacol; 2020 Jan; 171():113738. PubMed ID: 31786261
[TBL] [Abstract][Full Text] [Related]
26. Targeting the WNK-SPAK/OSR1 Pathway and Cation-Chloride Cotransporters for the Therapy of Stroke.
Josiah SS; Meor Azlan NF; Zhang J
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513812
[TBL] [Abstract][Full Text] [Related]
27. WNK4 is indispensable for the pathogenesis of pseudohypoaldosteronism type II caused by mutant KLHL3.
Susa K; Sohara E; Takahashi D; Okado T; Rai T; Uchida S
Biochem Biophys Res Commun; 2017 Sep; 491(3):727-732. PubMed ID: 28743496
[TBL] [Abstract][Full Text] [Related]
28. Regulation of NKCC2 activity by inhibitory SPAK isoforms: KS-SPAK is a more potent inhibitor than SPAK2.
Park HJ; Curry JN; McCormick JA
Am J Physiol Renal Physiol; 2013 Dec; 305(12):F1687-96. PubMed ID: 24133122
[TBL] [Abstract][Full Text] [Related]
29. Staurosporine and NEM mainly impair WNK-SPAK/OSR1 mediated phosphorylation of KCC2 and NKCC1.
Zhang J; Cordshagen A; Medina I; Nothwang HG; Wisniewski JR; Winklhofer M; Hartmann AM
PLoS One; 2020; 15(5):e0232967. PubMed ID: 32413057
[TBL] [Abstract][Full Text] [Related]
30. With no lysine L-WNK1 isoforms are negative regulators of the K+-Cl- cotransporters.
Mercado A; de Los Heros P; Melo Z; Chávez-Canales M; Murillo-de-Ozores AR; Moreno E; Bazúa-Valenti S; Vázquez N; Hadchouel J; Gamba G
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C54-66. PubMed ID: 27170636
[TBL] [Abstract][Full Text] [Related]
31. Renal TNFα activates the WNK phosphorylation cascade and contributes to salt-sensitive hypertension in chronic kidney disease.
Furusho T; Sohara E; Mandai S; Kikuchi H; Takahashi N; Fujimaru T; Hashimoto H; Arai Y; Ando F; Zeniya M; Mori T; Susa K; Isobe K; Nomura N; Yamamoto K; Okado T; Rai T; Uchida S
Kidney Int; 2020 Apr; 97(4):713-727. PubMed ID: 32059997
[TBL] [Abstract][Full Text] [Related]
32. WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1.
Moriguchi T; Urushiyama S; Hisamoto N; Iemura S; Uchida S; Natsume T; Matsumoto K; Shibuya H
J Biol Chem; 2005 Dec; 280(52):42685-93. PubMed ID: 16263722
[TBL] [Abstract][Full Text] [Related]
33. WNK1-OSR1/SPAK KINASE CASCADE IS IMPORTANT FOR ANGIOGENESIS.
Huang CL; Jian X; Yuh CH
Trans Am Clin Climatol Assoc; 2020; 131():140-146. PubMed ID: 32675854
[TBL] [Abstract][Full Text] [Related]
34. WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration.
Zhu W; Begum G; Pointer K; Clark PA; Yang SS; Lin SH; Kahle KT; Kuo JS; Sun D
Mol Cancer; 2014 Feb; 13():31. PubMed ID: 24555568
[TBL] [Abstract][Full Text] [Related]
35. The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters.
Alessi DR; Zhang J; Khanna A; Hochdörfer T; Shang Y; Kahle KT
Sci Signal; 2014 Jul; 7(334):re3. PubMed ID: 25028718
[TBL] [Abstract][Full Text] [Related]
36. The Photosensitising Clinical Agent Verteporfin Is an Inhibitor of SPAK and OSR1 Kinases.
AlAmri MA; Kadri H; Alderwick LJ; Jeeves M; Mehellou Y
Chembiochem; 2018 Oct; 19(19):2072-2080. PubMed ID: 29999233
[TBL] [Abstract][Full Text] [Related]
37. Phenotypes of pseudohypoaldosteronism type II caused by the WNK4 D561A missense mutation are dependent on the WNK-OSR1/SPAK kinase cascade.
Chiga M; Rafiqi FH; Alessi DR; Sohara E; Ohta A; Rai T; Sasaki S; Uchida S
J Cell Sci; 2011 May; 124(Pt 9):1391-5. PubMed ID: 21486947
[TBL] [Abstract][Full Text] [Related]
38. Interactions with WNK (with no lysine) family members regulate oxidative stress response 1 and ion co-transporter activity.
Sengupta S; Tu SW; Wedin K; Earnest S; Stippec S; Luby-Phelps K; Cobb MH
J Biol Chem; 2012 Nov; 287(45):37868-79. PubMed ID: 22989884
[TBL] [Abstract][Full Text] [Related]
39. Role of nitric oxide and WNK-SPAK/OSR1-KCC2 signaling in daily changes in GABAergic inhibition in the rat dorsal raphe neurons.
Kim MJ; Yang HJ; Kim Y; Kang I; Kim SS; Cho YW
Neuropharmacology; 2018 Jun; 135():355-367. PubMed ID: 29596900
[TBL] [Abstract][Full Text] [Related]
40. Kidney-specific WNK1 isoform (KS-WNK1) is a potent activator of WNK4 and NCC.
Argaiz ER; Chavez-Canales M; Ostrosky-Frid M; Rodríguez-Gama A; Vázquez N; Gonzalez-Rodriguez X; Garcia-Valdes J; Hadchouel J; Ellison D; Gamba G
Am J Physiol Renal Physiol; 2018 Sep; 315(3):F734-F745. PubMed ID: 29846116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
